Author: "Kim, Jae-Weon" / Publisher: american association for cancer research (aacr) - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Kim, Jae-Weon"' showing total 44 results

Start Over Author "Kim, Jae-Weon" Publisher american association for cancer research (aacr)

44 results on '"Kim, Jae-Weon"'

1. Supplementary Table S6 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

2. Supplementary Figure S3 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

3. Supplementary Appendix S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

4. Supplementary Figure S2 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

5. Supplementary Table S4 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

6. Supplementary Table S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

7. Supplementary Figure S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

8. Supplementary Table S6 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

9. Supplementary Table S7 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

10. Supplementary Table S5 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

11. Supplementary Table S3 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

12. Supplementary Table S4 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

13. Data from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

14. Supplementary Table S5 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

15. Supplementary Appendix S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

16. Supplementary Table S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

17. Supplementary Figure S2 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

18. Supplementary Table S7 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

19. Data from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

20. Supplementary Figure S3 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

21. Supplementary Table S2 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

22. Supplementary Table S3 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

23. Supplementary Figure S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, primary, Penson, Richard T., primary, O'Malley, David M., primary, Parkinson, Christine, primary, Roxburgh, Patricia, primary, Plummer, Ruth, primary, Im, Seock-Ah, primary, Imbimbo, Martina, primary, Ferguson, Michelle, primary, Rosengarten, Ora, primary, Steeghs, Neeltje, primary, Kim, Min Hwan, primary, Gal-Yam, Einav, primary, Tsoref, Daliah, primary, Kim, Jae-Hoon, primary, You, Benoit, primary, De Jonge, Maja, primary, Lalisang, Roy, primary, Gort, Eelke, primary, Bastian, Sara, primary, Meyer, Kassondra, primary, Feeney, Laura, primary, Baker, Nigel, primary, Ah-See, Mei-Lin, primary, Domchek, Susan M., primary, and Banerjee, Susana, primary
Published: 2024
Full Text: View/download PDF

24. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author: Drew, Yvette, primary, Kim, Jae-Weon, additional, Penson, Richard T., additional, O'Malley, David M., additional, Parkinson, Christine, additional, Roxburgh, Patricia, additional, Plummer, Ruth, additional, Im, Seock-Ah, additional, Imbimbo, Martina, additional, Ferguson, Michelle, additional, Rosengarten, Ora, additional, Steeghs, Neeltje, additional, Kim, Min Hwan, additional, Gal-Yam, Einav, additional, Tsoref, Daliah, additional, Kim, Jae-Hoon, additional, You, Benoit, additional, de Jonge, Maja, additional, Lalisang, Roy, additional, Gort, Eelke, additional, Bastian, Sara, additional, Meyer, Kassondra, additional, Feeney, Laura, additional, Baker, Nigel, additional, Ah-See, Mei-Lin, additional, Domchek, Susan M., additional, and Banerjee, Susana, additional
Published: 2023
Full Text: View/download PDF

25. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

26. Supplementary Figure from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

27. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

28. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

29. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

30. Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

31. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

32. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

33. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

34. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

35. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

36. Supplementary Figure from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

37. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

38. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

39. Supplementary Data from Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, primary, Kim, Myung Ji, primary, Kim, Sinae, primary, Lee, Eun Ji, primary, Park, Min Ji, primary, Kim, Jae-Weon, primary, Kim, Byoung-Gie, primary, Cho, Eun-Hae, primary, Chang, Suhwan, primary, Lee, Jung-Yun, primary, and Choi, Jung Kyoon, primary
Published: 2023
Full Text: View/download PDF

40. Abstract CT010: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (KGOG 3046/TRU-D)

Author: Park, Junsik, primary, Park, Eunhyang, additional, Joung, Je-Gun, additional, Lim, Myong Cheol, additional, Kim, Byoung-Gie, additional, Kim, Jae Weon, additional, Lee, Jung Bok, additional, Kim, Sunghoon, additional, Choi, Chel Hun, additional, Kim, Hee Seung, additional, Park, Sang Yoon, additional, Chung, Jongsuk, additional, and Lee, Jung-Yun, additional
Published: 2022
Full Text: View/download PDF

41. Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Author: Kang, Hyeon Gu, primary, Hwangbo, Haeun, additional, Kim, Myung Ji, additional, Kim, Sinae, additional, Lee, Eun Ji, additional, Park, Min Ji, additional, Kim, Jae-Weon, additional, Kim, Byoung-Gie, additional, Cho, Eun-Hae, additional, Chang, Suhwan, additional, Lee, Jung-Yun, additional, and Choi, Jung Kyoon, additional
Published: 2021
Full Text: View/download PDF

42. Abstract 652: Reproductive and hormonal factors and ovarian cancer: Case-control study

Author: ma, Seunghyun, primary, Park, Sue K., additional, Yoo, Keun-Young, additional, Kim, Tae Joong, additional, Kim, Byoung-Gie, additional, Kim, Yong-Man, additional, and Kim, Jae Weon, additional
Published: 2012
Full Text: View/download PDF

43. Abstract 1472: Bcl-3 as a carcinogenic factor in non-endometrioid endometrial carcinoma

Author: Lee, Yoo-Kyung, primary, Chung, Hyun Hoon, additional, Kim, Jae Weon, additional, Park, Noh-Hyun, additional, Kang, Soon-Beom, additional, and Song, Yong-Sang, additional
Published: 2010
Full Text: View/download PDF

44. Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer

Author: Jeon, Yong-Tark, primary, Kang, Sokbom, additional, Kang, Dae-Hee, additional, Yoo, Keun-Young, additional, Park, In-Ae, additional, Bang, Yung-Jue, additional, Kim, Jae Weon, additional, Park, Noh-Hyun, additional, Kang, Soon-Beom, additional, Lee, Hyo-Pyo, additional, and Song, Yong-Sang, additional
Published: 2004
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Journal

Database

44 results on '"Kim, Jae-Weon"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources